Immunoglobulin light chain amyloidosis is diagnosed late in patients with preexisting plasma cell dyscrasias

Taxiarchis Kourelis, Shaji K Kumar, Ronald S. Go, Prashant Kapoor, Robert A. Kyle, Francis K. Buadi, Morie Gertz, Martha Lacy, Suzanne R. Hayman, Nelson Leung, David M Dingli, John A. Lust, Yi Lin, Stephen R. Zeldenrust, S Vincent Rajkumar, Angela Dispenzieri

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

AL amyloidosis (AL) is rare and frequently remains undiagnosed until organ function is compromised, even among patients with known pre-existing untreated plasma cell dyscrasias (PCD). We identified 168 patients with AL amyloidosis who had a prior untreated PCD. The earliest symptom or sign (s/s) was defined as the first symptom reported by the patient that could be attributed to organ dysfunction caused by AL. The interval from the time of development of s/s to the establishment of diagnosis of AL (Interval-SA) was calculated. PCD diagnosis preceded recorded onset of s/s in 75% (114/152) of patients, with a median interval-SA for this group of 10 months. PCD was diagnosed after s/s in 25% (38/152) of patients, with a median interval-SA of 20 months. Overall survival (OS) from diagnosis of AL was not different between the two groups. AL amyloidosis patients with an identified pre-existing PCD had less advanced cardiac disease at AL diagnosis when compared to a control group of AL patients without pre-identified PCD. Long-term OS was not significantly superior among patients with a pre-identified PCD. In patients with "asymptomatic" PCD, symptoms and signs of AL amyloidosis should be solicited, since timely diagnosis is important in AL amyloidosis.

Original languageEnglish (US)
Pages (from-to)1051-1054
Number of pages4
JournalAmerican Journal of Hematology
Volume89
Issue number11
DOIs
StatePublished - Nov 1 2014

Fingerprint

Immunoglobulin Light Chains
Paraproteinemias
Amyloidosis
Signs and Symptoms
Survival

ASJC Scopus subject areas

  • Hematology

Cite this

Immunoglobulin light chain amyloidosis is diagnosed late in patients with preexisting plasma cell dyscrasias. / Kourelis, Taxiarchis; Kumar, Shaji K; Go, Ronald S.; Kapoor, Prashant; Kyle, Robert A.; Buadi, Francis K.; Gertz, Morie; Lacy, Martha; Hayman, Suzanne R.; Leung, Nelson; Dingli, David M; Lust, John A.; Lin, Yi; Zeldenrust, Stephen R.; Rajkumar, S Vincent; Dispenzieri, Angela.

In: American Journal of Hematology, Vol. 89, No. 11, 01.11.2014, p. 1051-1054.

Research output: Contribution to journalArticle

@article{5b802a61925841df90cbfce399a0eb58,
title = "Immunoglobulin light chain amyloidosis is diagnosed late in patients with preexisting plasma cell dyscrasias",
abstract = "AL amyloidosis (AL) is rare and frequently remains undiagnosed until organ function is compromised, even among patients with known pre-existing untreated plasma cell dyscrasias (PCD). We identified 168 patients with AL amyloidosis who had a prior untreated PCD. The earliest symptom or sign (s/s) was defined as the first symptom reported by the patient that could be attributed to organ dysfunction caused by AL. The interval from the time of development of s/s to the establishment of diagnosis of AL (Interval-SA) was calculated. PCD diagnosis preceded recorded onset of s/s in 75{\%} (114/152) of patients, with a median interval-SA for this group of 10 months. PCD was diagnosed after s/s in 25{\%} (38/152) of patients, with a median interval-SA of 20 months. Overall survival (OS) from diagnosis of AL was not different between the two groups. AL amyloidosis patients with an identified pre-existing PCD had less advanced cardiac disease at AL diagnosis when compared to a control group of AL patients without pre-identified PCD. Long-term OS was not significantly superior among patients with a pre-identified PCD. In patients with {"}asymptomatic{"} PCD, symptoms and signs of AL amyloidosis should be solicited, since timely diagnosis is important in AL amyloidosis.",
author = "Taxiarchis Kourelis and Kumar, {Shaji K} and Go, {Ronald S.} and Prashant Kapoor and Kyle, {Robert A.} and Buadi, {Francis K.} and Morie Gertz and Martha Lacy and Hayman, {Suzanne R.} and Nelson Leung and Dingli, {David M} and Lust, {John A.} and Yi Lin and Zeldenrust, {Stephen R.} and Rajkumar, {S Vincent} and Angela Dispenzieri",
year = "2014",
month = "11",
day = "1",
doi = "10.1002/ajh.23827",
language = "English (US)",
volume = "89",
pages = "1051--1054",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "11",

}

TY - JOUR

T1 - Immunoglobulin light chain amyloidosis is diagnosed late in patients with preexisting plasma cell dyscrasias

AU - Kourelis, Taxiarchis

AU - Kumar, Shaji K

AU - Go, Ronald S.

AU - Kapoor, Prashant

AU - Kyle, Robert A.

AU - Buadi, Francis K.

AU - Gertz, Morie

AU - Lacy, Martha

AU - Hayman, Suzanne R.

AU - Leung, Nelson

AU - Dingli, David M

AU - Lust, John A.

AU - Lin, Yi

AU - Zeldenrust, Stephen R.

AU - Rajkumar, S Vincent

AU - Dispenzieri, Angela

PY - 2014/11/1

Y1 - 2014/11/1

N2 - AL amyloidosis (AL) is rare and frequently remains undiagnosed until organ function is compromised, even among patients with known pre-existing untreated plasma cell dyscrasias (PCD). We identified 168 patients with AL amyloidosis who had a prior untreated PCD. The earliest symptom or sign (s/s) was defined as the first symptom reported by the patient that could be attributed to organ dysfunction caused by AL. The interval from the time of development of s/s to the establishment of diagnosis of AL (Interval-SA) was calculated. PCD diagnosis preceded recorded onset of s/s in 75% (114/152) of patients, with a median interval-SA for this group of 10 months. PCD was diagnosed after s/s in 25% (38/152) of patients, with a median interval-SA of 20 months. Overall survival (OS) from diagnosis of AL was not different between the two groups. AL amyloidosis patients with an identified pre-existing PCD had less advanced cardiac disease at AL diagnosis when compared to a control group of AL patients without pre-identified PCD. Long-term OS was not significantly superior among patients with a pre-identified PCD. In patients with "asymptomatic" PCD, symptoms and signs of AL amyloidosis should be solicited, since timely diagnosis is important in AL amyloidosis.

AB - AL amyloidosis (AL) is rare and frequently remains undiagnosed until organ function is compromised, even among patients with known pre-existing untreated plasma cell dyscrasias (PCD). We identified 168 patients with AL amyloidosis who had a prior untreated PCD. The earliest symptom or sign (s/s) was defined as the first symptom reported by the patient that could be attributed to organ dysfunction caused by AL. The interval from the time of development of s/s to the establishment of diagnosis of AL (Interval-SA) was calculated. PCD diagnosis preceded recorded onset of s/s in 75% (114/152) of patients, with a median interval-SA for this group of 10 months. PCD was diagnosed after s/s in 25% (38/152) of patients, with a median interval-SA of 20 months. Overall survival (OS) from diagnosis of AL was not different between the two groups. AL amyloidosis patients with an identified pre-existing PCD had less advanced cardiac disease at AL diagnosis when compared to a control group of AL patients without pre-identified PCD. Long-term OS was not significantly superior among patients with a pre-identified PCD. In patients with "asymptomatic" PCD, symptoms and signs of AL amyloidosis should be solicited, since timely diagnosis is important in AL amyloidosis.

UR - http://www.scopus.com/inward/record.url?scp=85027939245&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027939245&partnerID=8YFLogxK

U2 - 10.1002/ajh.23827

DO - 10.1002/ajh.23827

M3 - Article

C2 - 25111004

AN - SCOPUS:85027939245

VL - 89

SP - 1051

EP - 1054

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 11

ER -